Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BICARA: ficerafusp alfa plus nivolumab in platinum-refractory head and neck squamous cell carcinoma
2025-521437-88-00Phase 2Authorised
- Sponsor
- GORTEC
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ficerafusp alfa and nivolumab in head and neck squamous cell carcinoma (HNSCC), sponsored by GORTEC. Primary endpoint: objective response rate. Planned start Jul 2026; status: authorised.
02
Drugs
ficerafusp alfanivolumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2025-521437-88-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521437-88-00.